Fig. 1.

A) Association between normalized activated protein C sensitivity ratio (nAPCsr) data and relative risk of venous thromboembolism in women using combined oral contraceptives; B) mean thrombogram [2.5^th–97.5^th percentile] of childbearing age women not using any hormonal contraception (baseline population) (n = 86; yellow) and mean thrombogram [95% CI of the mean] after 6 cycles of estetrol 15 mg associated with drospirenone 3 mg (n = 34; pink); C) mean thrombogram [2.5^th–97.5^th percentile] of untreated postmenopausal women (n = 168; orange) and mean thrombogram [95% CI of the mean] after 12 weeks of estetrol 15 mg (n = 32, red)

CI – confidence interval, COC – combined oral contraceptive, CPA – cyproterone acetate, DNG –dienogest, DRSP – drospirenone, DSG – desogestrel, EE – ethinyloestradiol, E₂ – oestradiol, E₄ – estetrol, GSD – gestodene, LNG – levonorgestrel, nAPCsr – normalized activated protein C sensitivity ratio, NOMAC – nomegestrol acetate, RR – relative risk, SD – standard deviation, VTE – venous thromboembolism